Status:
COMPLETED
Use of Bevacizumab in Trabeculectomy Surgery
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborating Sponsors:
Glaucoma Research Society of Canada
Conditions:
Glaucoma
Optic Neuropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
When a patient with glaucoma who has a pressure that is too high and causing damage to their vision, despite receiving the maximum amount of medication that can be tolerated, the decision is made to h...
Detailed Description
The usual treatment is to not have an injection of Bevacizumab on the third through fifth day after trabeculectomy surgery. Topical anaesthetic drops to numb the eye will be given, prior to being give...
Eligibility Criteria
Inclusion
- Age more than 18 years old
- Patients with glaucoma that is inadequately controlled on maximal tolerated medical therapy and scheduled for trabeculectomy surgery (with/without combined cataract extraction)
- Decision makers fluent in English
- Decision makers able to understand and read consent form
Exclusion
- Patients with active intraocular inflammation/uveitis or neovascular glaucoma
- History of previous trabeculectomy surgery or prior retinal detachment with scleral buckle placement in the surgical eye
- Aphakia in surgical eye
- Pregnant and nursing women
- Unable to fulfill inclusion criteria
- Refusal of consent
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT01166594
Start Date
June 1 2010
End Date
December 1 2013
Last Update
August 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Hospital
Toronto, Ontario, Canada, M4N 3M5